Navigation Links
Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
Date:11/21/2007

e three weeks. Brostallicin was escalated from 5 to 7 to 9 mg/m2 with a fixed dose of cDDP of 75 mg/m2. To review the poster for more detailed information, please go to http://www.CTICSeattle.com.

About Brostallicin

Brostallicin, a novel synthetic second-generation DNA minor groove binder, has potent cancer killing activity and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted therapies in preclinical experimental tumors models. Brostallicin binds covalently to DNA within the DNA minor groove interfering with DNA division and leading to tumor cell death. More than 200 patients have been treated with brostallicin in single-agent and combination studies. Brostallicin had predictable and predominantly hematologic toxicities. Activity was demonstrated in a number of solid tumor types. A phase II study of brostallicin in relapsed/refractory soft tissue sarcoma met its pre-defined activity and safety hurdles and resulted in a first-line phase II study that

is currently being conducted by the European Organization for Research and Treatment of Cancer (EORTC).

About Systems Medicine (SM)

In July 2007, CTI acquired Systems Medicine (SM), a privately-held oncology company, in a stock-for-stock merger. SM applies a systems biology approach to drug development, combining pharmacogenomics and bioinformatics with experienced preclinical, clinical, and regulatory expertise to find and exploit a specific cancer's 'context of vulnerability.' Specifically, SM defines the molecular and genetic alterations (context) that cause cancer cells to be particularly sensitive (vulnerable) to a drug or combination of drugs -- the 'context of vulnerability'.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer mo
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Phase III Trial Finds Pharmaxis Bronchitol Effective
9. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
10. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Greenville, SC (PRWEB) August 22, 2014 ... that indisputable acknowledgement is a national disgrace. Furthermore, ... part in establishing the current, deplorable state of ... outlined "5 great mistakes," to merely serve as ... convey the extent of colossal failure(s) that have ...
(Date:8/21/2014)... team including DESY scientists has observed tiny quantum vortices ... in the journal Science that the exotic ... nanodroplets. It is the first time that the quantum ... of what is known as superfluid helium, have been ... expectations," says Andrey Vilesov of the University of Southern ...
(Date:8/21/2014)... , Aug. 21, 2014 Telomere Biosciences, ... their Nutraceutical "TELO-20 for Dogs" with Telomerase ... supplement in the world for dogs. Telomeres are ... chromosome in the body. A wealth of ground-breaking ... in Telomere Science and Aging, including Nobel laureates, ...
(Date:8/21/2014)... 2014 OTC Markets Group Inc. ... biotechnology company, on its approval to list on ... OTCQX®, the best marketplace for established U.S. and ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... of its growth strategy and achievement of this ...
Breaking Biology Technology:5 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2Scientists observe quantum vortices in cold helium droplets 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2
... BioSciences, Inc. (OTC Bulletin Board: GNLK ... that it ranked number 33 on Technology Fast 500 ... growing technology, media, telecommunications, life sciences and clean technology ... the period 2006-2010. GeneLink,s chief executive ...
... Inc ., a late-stage epigenetics oncology company, announced today that members ... BIO Investor Forum , San Francisco, CA, October ... Target , Panel Discussion: HDACi and Their Progress in the Clinic, ... Healthcare Conference , New York, NY, November 16, 1:30 PM ET ...
... 24, 2011 Modern Plastics, one of the largest ... plastics, has become ISO 13485-2003 certified for the distribution ... Resin. "This is an extraordinary achievement ... service and quality," said Bing J. Carbone, President at ...
Cached Biology Technology:GeneLink BioSciences, Inc. Ranked Number 33 Fastest Growing Company in North America on Deloitte's 2011 Technology Fast 500™ 2GeneLink BioSciences, Inc. Ranked Number 33 Fastest Growing Company in North America on Deloitte's 2011 Technology Fast 500™ 3Syndax Pharmaceuticals to Present at Upcoming Fall Conferences 2
(Date:8/21/2014)... of researchers at Louisiana Tech University has ... consumer-grade 3D printers and materials to fabricate ... and chemotherapeutic compounds for targeted drug delivery. ... and research faculty from Louisiana Tech,s biomedical ... create filament extruders that can make medical-quality ...
(Date:8/21/2014)... resulting in severe abdominal pain, vomiting and systemic inflammation. ... diagnosed with the disease resulting in 1000 deaths. There ... intravenous fluid and nutritional support. , Dr Jason ... the research, said "The major causes of pancreatitis include ... intake combined with a high fat diet. In fact, ...
(Date:8/20/2014)... Researchers at Huntsman Cancer Institute (HCI) at the University ... the gene that encodes BCR-ABL, the unregulated enzyme driving ... the American Cancer Society, nearly 6,000 new cases of ... in use, called tyrosine kinase inhibitors (TKIs), target BCR-ABL ... not cure CML but control it in a way ...
Breaking Biology News(10 mins):Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3Insulin offers new hope for the treatment of acute pancreatitis 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... the Smithsonian Institution and the Hawaii Institute of Marine ... created the first frozen bank for Hawaiian corals in ... preserve their diversity in Hawaii. Mary Hagedorn, an adjunct ... the Smithsonian Conservation Biology Institute, leads the laboratory at ...
... underlay many cancers. Rui Martinho at the Instituto Gulbenkian ... in Ghent (Belgium) and Bergen (Norway) will use the ... identified in the test-tube, impact on the way cells ... the Association for International Cancer Research (AICR), will provide ...
... of an old antibiotic may help diabetics avoid a stroke ... researchers report. Minocycline, a drug already under study at ... blood vessels in the brain that increases their stroke risk ... Dr. Adviye Ergul, physiologist in the MCG Schools of Medicine ...
Cached Biology News:Smithsonian scientists help create first frozen repository for Hawaiian coral 2Understanding cancer using the fruit fly 2Antibiotic may reduce stroke risk and injury in diabetics 2
... Desselberger (1995) • This book is ... classical and molecular techniques currently used ... and analysis of virus-specific antibodies and ... presented covering immunoassays, blotting and hybridization ...
Bovine Serum...
Mus musculus junctophilin 2 (Jph2) Antigen: Recombinant Protein...
2.0 GHz Compaq Computer with 512 MB RAM, 32 MB AGP Graphics Card, 40 GB Hard Drive, 1 Serial Port & Open PCI Slot, Windows 2000 OS, MS Office, CD Read/Writer and 18 Flat Panel Monitor...
Biology Products: